If anyone has any information pursuant to this, please let me know.
Yes. It is very well defined in there.
Because, Mr. James, I wanted to ask, the regulator, he has to follow the law. How do you answer the question of higher costs?
I think this was at the end of the term, and I think as you have listened to the questions in a Committee that is the protector of competiti...
I think there is an enormous amount of right on the side of community and small pharmacies. It is a mountain of rightness on that.
I believe that what we tried to do in the Affordable Care Act, close the doughnut hole, keep people alive who have preexisting diseases is a...
I think they have a valuable role, even as a small business, but as a familiar face to the community.
If we tried to glean all of the information, would you be able to provide data?
Do we define small pharmacies in that legislation?
I would say, since this is the first time, Congresswoman and Congressman Smith, that I have been at this table since the loss of our dear ch...
we have to have a respectful balance.
I believe this is an important hearing that allows us to deal with this issue and be thoughtful, and see how we can come to a reasoned respo...
And the costs will be on the ultimate product that the consumer is coming to the pharmacy for.
But, in terms of your actual evaluation of Express Scripts-Medco merger, but other actions by these companies, many of them we know their na...
I am proud to come from a State with a strong history of leadership in medical discovery.
We cannot allow this to continue as the status quo.
It is crucial that, during this reauthorization, we update our regulatory oversight and infrastructure at the FDA.
Thank you to the panelists for your remarks today.
